Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions

Critical Care Medicine

Volumn 37, Issue 1, 2009, Pages 19-25

  Gentry, Chris A ^a   Gross, Kristin Busse ^a   Sud, Bhanu ^b   Drevets, Douglas A ^b  

^a Affairs Medical Center   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Bleeding precautions; Drotrecogin alfa; Sepsis

Indexed keywords

ANTICOAGULANT AGENT; DROTRECOGIN; HEPARIN; THROMBOCYTE SLOWING FACTOR; ANTIINFECTIVE AGENT; PROTEIN C; RECOMBINANT PROTEIN;

ADULT; ADVERSE OUTCOME; ARTICLE; BLEEDING; BLEEDING TENDENCY; BLOODSTREAM INFECTION; CONTROLLED STUDY; DRUG FATALITY; FATALITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITAL DISCHARGE; HUMAN; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEPSIS; STROKE; SUBARACHNOID HEMORRHAGE; TERTIARY HEALTH CARE; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; HOSPITALIZATION; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY;

ANTI-INFECTIVE AGENTS; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PROTEIN C; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SEPSIS; SEVERITY OF ILLNESS INDEX;

EID: 59649104743     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318192843b     Document Type: Article

References (17)

1. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
2. Bernard GR: Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med 2003; 31:S85-S93
3. Eichacker PQ, Natanson C: Recombinant human activated protein C in sepsis: Inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials. Crit Care Med 2003; 31:S94-S96
4. Deans KJ, Minneci PC, Banks SM, et al: Substantiating the concerns about recombinant human activated protein C use in sepsis. Crit Care Med 2004; 32:2542-2543
5. Barie PS: An opinion too far - The campaign against the surviving sepsis campaign. Surg Infect 2006; 7:485-488
6. Durbin CG: Is industry guiding the sepsis guidelines? A perspective. Crit Care Med 2007; 35:689-691
7. O'Brien JM: Recombinant human activated protein C sentenced to the death of a thousand cuts? Crit Care Med 2007; 35:1609-1610
8. Important drug warning: Mortality in patients with single organ dysfunction and recent surgery. Available at: http://www.fda.gov/medwatch/ SAFETY/2005/xigris-DHCP. pdf. Accessed July 3, 2007
9. Discontinuation of study F1K-MC-EVBP, investigation of the efficacy and safety of drotrecogin alfa (activated) in pediatric severe sepsis. Available at: http://www.fda.govmedwatch/SAFETY/2005/Xigris-dearhcp-4-21-05.pdf Accessed July 3, 2007
10. Product Information - Xigris. Indianapolis, Indiana, Eli Lilly and Co, 2007
11. VHA Infectious Diseases Program Office, Pulmonary & Critical Care Field Advisory Group, and Pharmacy Benefits Management - Medical Advisory Panel. Criteria Checklist for Drotrecogin Alfa (activated). Available at: http://www.pbm.va.gov/criteria/drotrecogincriteriachecklist.pdf.Accessed July 3, 2007
12. Abraham E, Laterre PF, Garg R, et al: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341
13. Vincent JL, Bernard GR, Beale R, et al: Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment. Crit Care Med 2005; 33:2266-2277
14. Levi M, Levy M, Williams MD, et al: Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007; 176: 483-490
15. Transcripts of the Anti-Infective Drugs Advisory Committee: Food and Drug Administration Center for Drug Evaluation and Research. October 16, 2001. Gaithersburg, Maryland
16. Kanji s, Perreault MM, Chant C, et al: Evaluating the use of drotrecogin alfa (activated) in adult severe sepsis: A Canadian multi-center observational study. Intensive Care Med 2007; 33:517-523
17. Bertolini G, Rossi C, Anghileri A, et al: Use of drotrecogin alfa (activated) in Italian intensive care units: The results of a nationwide survey. Intensive Care Med 2007; 33:426-434